EXACT Sciences Corporation  

(Public, NASDAQ:EXAS)   Watch this stock  
Find more results for EXAS
-0.29 (-1.18%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.63 - 24.48
52 week 15.12 - 32.85
Open 24.33
Vol / Avg. 1.31M/1.72M
Mkt cap 2.35B
P/E     -
Div/yield     -
EPS -1.61
Shares 95.91M
Beta 1.29
Inst. own 92%
Oct 26, 2015
Q3 2015 Exact Sciences Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 23, 2015
Exact Sciences Corp Annual Shareholders Meeting - Webcast
Jul 20, 2015
Q2 2015 Exact Sciences Corp Earnings Call
Jul 20, 2015
Q2 2015 Exact Sciences Corp Earnings Release
Jun 25, 2015
Exact Sciences Corp Investor & Analyst Day
Jun 11, 2015
Exact Sciences Corp at Goldman Sachs Healthcare Conference
Jun 10, 2015
Exact Sciences Corp at William Blair Annual Growth Stock Conference
Jun 4, 2015
Exact Sciences Corp at Jefferies Global Healthcare Conference
May 19, 2015
Exact Sciences Corp at UBS Global Healthcare Conference
May 12, 2015
Exact Sciences Corp at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -481.17% -5564.40%
Operating margin -484.86% -5591.71%
EBITD margin - -5385.37%
Return on average assets -58.93% -43.55%
Return on average equity -64.88% -47.16%
Employees 236 -
CDP Score - -


441 Charmany Dr
MADISON, WI 53719-1234
United States - Map
+1-608-2845700 (Phone)
+1-608-2845701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non‑invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non‑invasive stool‑based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody‑based fecal immunochemical test (FIT). The Company's Cologuard test is designed to detect pre‑cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre‑cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The company's test also detects blood in stool, utilizing an antibody based FIT test.

Officers and directors

Kevin T. Conroy Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
William J. Megan Principal Financial Officer, Senior Vice President - Finance
Age: 58
Bio & Compensation  - Reuters
Maneesh K. Arora Chief Operating Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
Graham P. Lidgard Ph.D. Senior Vice President, Chief Scientific Officer
Age: 66
Bio & Compensation  - Reuters
David A. Thompson Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
Thomas D. Carey Independent Director
Age: 53
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel J. Levangie Independent Director
Age: 64
Bio & Compensation  - Reuters
Katherine S. Napier Independent Director
Age: 60
Bio & Compensation  - Reuters